Development of a novel cognitive composite outcome to assess therapeutic effects of exercise in the EXERT trial for adults with MCI: The ADAS‐Cog‐Exec-Reference-Cited by-同舟云学术

Development of a novel cognitive composite outcome to assess therapeutic effects of exercise in the EXERT trial for adults with MCI: The ADAS‐Cog‐Exec

Published:2020-01 Issue:1 Volume:6 Page:
ISSN:2352-8737
Container-title:Alzheimer's & Dementia: Translational Research & Clinical Interventions
language:en
Short-container-title:A&D Transl Res & Clin Interv

Author:

Jacobs Diane M.¹²³,Thomas Ronald G.²⁴,Salmon David P.¹²³,Jin Shelia²⁴,Feldman Howard H.¹²³,Cotman Carl W.⁵,Baker Laura D.⁶, ,

Affiliation:

1. Department of Neurosciences University of California San Diego La Jolla California USA

2. Alzheimer's Disease Cooperative Study University of California San Diego La Jolla California

3. Shiley‐Marcos Alzheimer's Disease Research Center University of California San Diego La Jolla California USA

4. Division of Biostatistics Department of Family Medicine & Public Health University of California San Diego La Jolla California USA

5. Institute for Memory Impairments and Neurological Disorders University of California Irvine Irvine California USA

6. Department of Internal Medicine–Geriatrics Wake Forest School of Medicine Winston‐Salem North Carolina USA

Publisher

Wiley

Subject

Psychiatry and Mental health,Neurology (clinical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/trc2.12059

Reference32 articles.

1. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy;Mohs RC;Psychopharmacol Bull,1983

2. The Preclinical Alzheimer Cognitive Composite

3. An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease

4. The ADAS‐Cog revisited: Novel composite scales based on ADAS‐Cog to improve efficiency in MCI and early AD trials

5. Linear combinations of multiple outcome measures to improve the power of efficacy analysis – application to clinical trials on early-stage Alzheimer's disease

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer’s disease (BenfoTeam);PLOS ONE;2024-05-29

2. Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer’s disease (BenfoTeam);2024-04-19

3. ADSS: A Composite Score to Detect Disease Progression in Alzheimer’s Disease;Journal of Alzheimer's Disease Reports;2024-02-20

4. Applied behavioral analysis for the skill performance of children with autism spectrum disorder;Frontiers in Psychiatry;2023-04-26

5. APOE ε4 status and plasma p-tau181 interact to influence cognitive performance among non-demented older adults;Neuroscience Letters;2023-02